myocardial biology and the prospects of developing effective regeneration/repair protocols: Is the adult myocardium a self-renewing tissue? If so, what is the physiological significance of the self-renewal? Are the c-kit+ cells the regenerative/repair agents? If not, which are these regenerative agents? Clarification of the reason(s) for the reported discrepancies is of high priority, not only for cardiac biology but also for the future of the field of myocardial repair and regeneration.
Discrepant and even contradictory results on a given topic are nothing new in science, even when the experiments are properly planned and the results accurately reported. In most cases the discrepancies are often due to a misinterpretation of the power of the experimental system(s) used which often leads to the over-and/or mis-interpretation of the results. The latter appears to be main issue with the van Berlo et al. paper.
Not all Cre/LoxP cell-tracking systems provide reliable answers
One perennial conundrum in cell biology has been the search for an efficient and accurate method of tracking the cell lineage origin as well as the fate of a given cell type, both during development and in adulthood. The development of the Cre/LoxP system of constitutive and conditional gene targeting together with trans-or knocked-in genes seemed the ideal procedure for fate mapping of specific cells. Inducible or regulated Cre-expressing mouse lines are increasingly popular because they significantly improve temporal and spatial targeting of genes (4) . The most widely used inducible Cre lines utilise a Cre fused to a mutant ligand-binding domain of the oestrogen receptor (Cre-ER, mER-Cre-mER or Cre-ER T2 ) where Cre-ER, mER-Cre-mER or Cre-ER T2 activation depends on the selective oestrogen receptor modulator tamoxifen (4) .
Although the constitutive and conditional Cre/loxP systems are both extremely powerful, they has several drawbacks that need to be properly controlled to avoid erroneous interpretation of observed results (4) . As the van Berlo et al., work is exclusively based on the efficiency and fidelity of the Cre knock-in in the c-kit locus to track c-kit+ cell lineage fate, one must consider the main shortcomings of this recombination system that are summarized in Table 1 .
Therefore, considering these shortcomings, the conclusions reached with the Cre/lox system are only as reliable as the specific controls carried out to insure that the system performance is appropriate to unambiguously answer the questions addressed by the experiment. Table 2 summarizes the three controls that are particularly important. Unless these conditions are fulfilled the results of a Cre/lox experiment are un-interpretable. This is even more so when the results are negative because there is low or absent identifiable marked progeny of the target cells, as is the case of the results of van Berlo et al. These caveats are particularly important in light of the very complex and yet not fully elucidated c-kit gene regulation (6) . In fact, all the c-kit transgenic or knock-ins produced to track c-kit expressing cells are far from closely recapitulating c-kit expression and function either in development or adult life (6, 7) . It is evident that both the constitutive and regulated Cre c-kit gene mutated mice lines used by van Berlo et al., are c-kit hypomorphs, most likely hemizygous null, which are equivalent to the W/+ mutant mice (8) . While the typical signs of a c-kit hemizygous null allele (white spots on the belly, paws and tip of the tail) are not clearly reported in the paper, this conclusion is confirmed by the fact that the homozygous animals are not viable at birth and mostly die in utero. Whether the level of Cre expression from the mutated allele is sufficient to produce recombination in all or most of the c-kit expressing cells is unknown, except that there is recombination in cells/tissues with high endogenous c-kit expression.
The authors provided data showing recombination in several cell types, including myocardial cells, but not in the cells relevant to the results, i.e. the c-kit+ eCSCs. The reported recombination in total c-kit+ bone marrow cells and in myocyte-depleted c-kit+ cardiac cells is not relevant to the efficacy of the Cre/lox set-up because it is not specified which are the c-kit+ cell types recombined and which are not. In the constitutive Cre-IRES-nGFPxR26R-eGFP mice if the recombination were spatially and temporally correct, the majority (if not all) of blood cells in the adult should be labelled, as c-kit is expressed in all the embryonic cells with hematopoietic activity. Yet this piece of evidence is not provided. Furthermore, bone marrow and myocardial c-kit+ cells are complex cell mixtures with <10% representing the Hematopoietic Stem Cells (HSCs) and eCSCs, respectively (9) (10) (11) . Labelling even the majority of bone marrow c-kit+ cells might not be sufficient to follow blood cell lineage origin and specification. For that it is necessary to tag the long-term repopulating Sca-1+/c-kit+ (LSK) cells. The same applies to the myocardium where the most abundant c-kit+ cells are not the eCSCs but mast and endothelial cells and their precursors (10) . If cardiac mast cells (c-kit+CD45+) or endothelial progenitor cells (ckit+CD34+/CD31+) are labelled, then only their differentiation into inflammatory and endothelial cells or their fusion can be quantitatively assessed (which indeed van Berlo et al. appropriately measured) but not the fate of the c-kit+ eCSCs (c-kit+CD45−CD34−CD31−). Unfortunately, no data is presented about the recombination efficiency in cells with intermediate/low c-kit expression, such as HSCs and primordial germ cells (PGCs). Remarkably, even less is known about the recombination rate in the c-kit+ eCSCs because the authors did not isolate, quantify or in any way analyse these cells. In fact, the recombination efficiency in the c-kit+ eCSCs is an indispensable piece of information and the main driver for the conclusions derived from the results reported but it is never specifically assessed in the paper itself or in the additional information. That in vitro the eGFP, Kit-Cre allele expressing cells (eGFP+ c-Kit-Cre+) isolated from the constitutive Cre-IRES-nGFPxR26R-eGFP mice induce expression of cardiomyocyte markers (yet fail to differentiate into functionally competent cardiomyocytes) in response to dexamethasone is not evidence that eGFP+ Kit-Cre+ cells are eCSCs with myogenic progenitor properties, as erroneously suggested by the authors, because the true progenitors fully differentiate into beating myocytes in vitro and in vivo (2, 3, 11) . Moreover, that eGFP+ Kit-Cre+ cells in vitro express contractile protein genes is in line with the report that endothelial cells can acquire cardiomyogenic phenotypes in vitro and in vivo (12) . To substantiate that the cells analysed in vitro were true cardiac stem/progenitor cells, the authors should have rigorously tested the eGFP+c-kit-Cre+ cells for prototypical stem cell properties including clonogenicity, multipotency, self-renewal and in vivo regenerative potential.
Therefore, the first question that should have been but was not answered, is whether in either the constitutive or the conditional mice there was enough Cre produced to recombine a high/sufficient percentage of the c-kit+ eCSCs in order to track their fate. Without knowing the actual number/fraction of c-kit+ eCSCs labelled by the mouse genetic strategy, it is impossible to quantitatively measure their contribution to the formation of cardiomyocytes or to any other cell type.
The significant weakness of the Cre (and mER-Cre-mER in particular) knock-in in the c-kit gene and its failure to faithfully recapitulate the temporal and tissue-specific pattern of c-kit gene expression have been elegantly documented in two previous papers where a similar (actually better as a CreER T2 instead of a mER-Cre-mER construct was knocked-in) conditional Cre knock-in within the c-kit gene was employed (13, 14) . Remarkably, using similar strategies as van Berlo et al. c-kit+ eCSCs, by definition, express c-kit, which it is used for their isolation. However, the level of c-kit expression by the c-kit+ eCSCs in several strains of mice tested is significantly lower than in the HSCs (Torella et al. unpublished). As the c-kit Cre T2 knock-in (with its higher affinity for tamoxifen and higher recombination efficiency) recombines <10% of the HSCs (even after a longer pulse with tamoxifen-added chow) (14) , it is likely that an even lower fraction, if any, of c-kit+ eCSCs are recombined in the Cre/lox strategy of Molkentin's group. Independently of the correctness of the above conclusion, it is indisputable that the efficiency of recombination in the c-kit+ eCSCs, which is the main subject of the paper, should have been determined before attempting to evaluate their contribution to the myocardium using a model which is completely dependent on the efficiency of recombination to turn on the expression of the reporter gene. Without these data, their results are inconclusive and qualitative at best.
The authors in the supplementary discussion section reported "as a minor concern that the levels of new cardiomyocyte formation from the c-kit+ lineage reported …. may be under representative due to replacement of one functional Kit allele. Thus, there could be less c-kit+ "progenitor-like" activity in the hearts of these mice due to only a 50% dosage of c-kit protein". Also, they acknowledged, "another
potential issue is if c-kit+ cells present in the heart express the Kit locus (and Cre) at levels below the threshold of the Cre recombinase-based system. If this were the case it would again under-represent the total number of potential cardiomyocytes as being labeled from the c-kit+ lineage. However, Cre-based lineage tracing is a widely accepted standard for relevant gene expression, so the opposite argument could easily be made that if expression is below the Cre-threshold, it may not be physiologically meaningful Kit allele expression, and hence these cells are really not c-kit".
Clearly, these caveats should have been experimentally addressed particularly given the significance of the data discussed above and the fact that many bona fide c-kit+ cells do not recombine (13, 14) .
There are two additional issues that might also affect the interpretation of the results of van Berlo et al. First, the inner cell mass (ICM) cells of the blastocyst (i.e. the ESCs) express intermediate but significant levels of c-kit (15) . The level of c-kit expression is even higher in the primordial germ cells (7, 16) . Therefore, if the Cre knock-ins in the c-kit locus had recapitulated normal temporal and spatial expression of the gene, as it is assumed in the paper, all or most of the cells in the constitutive Cre expression mice should have been labelled along with their progeny. That the constitutive knock-in does not recombines the reporter gene in all the descendants of the ICM (the whole embryo) or that the male mice do not produce labelled progeny should have alerted the authors that something was amiss. Additionally, while it is still unknown whether myocardial development and myocytes in particular are dependent on an embryonic cardiac progenitor expressing c-kit, the absence of a significant recombination in the ESCs by the Cre-IRES-nGFP knock-in directly questions the quantitation of labelled cardiomyocytes at birth and at 4 to 12 post-natal weeks in the constitutive c-kit
Cre/+ //R26R-eGFP mice in Van Berlo's paper. Second, the authors overlooked the potential effect of producing a c-kit null allele in the targeted cells because targeting Cre to c-kit Exon 1 alters normal c-kit receptor activity (16) . This fact was used to identify which cells depend on physiological c-kit activity for their proper function, as is the case for most stem cells (14) . Therefore, it remains to be determined whether the null allele has altered the growth and/or differentiation properties of the c-kit+ eCSCs (some c-kit mutant mice have a cardiac phenotype, (8) ) in response to myocardial damage and/or these cells have been outcompeted by others not expressing the Cre knock-in (c-kit negative eCSCs).
In conclusion, although the data presented by van Berlo et al., have confirmed that c-kit+ cells fulfil the criteria of true cardiac stem/progenitor cells in development and adult life because some gave rise to cardiomyocytes, smooth muscle and endothelial cells, we believe that until the significant issues left unanswered by the report --particularly the efficiency of Cre recombinase in the models used--are satisfactorily addressed, their main conclusion that c-kit+ cells minimally contribute cardiomyocytes to the heart should be taken with extreme caution because it has not been tested by the experiments performed and certainly not proven by the data presented. Furthermore, it must be underlined that the employed cre-lox systems by their very nature, when working properly would label any cell expressing ckit at any time during development and post-natal life or during the tamoxifen treatment. Therefore, this system cannot distinguish between a single cell population with multipotent differentiation potential from several unipotent ones. This can be only be ascertained by single cell cloning and differentiation of the putative stem/progenitor cell in vitro and its transplantation in vivo. The multipotent and regenerative properties of c-kit+ eCSCs have been reproducibly and robustly ascertained (2,3) and these results are not challenged by the results of van Berlo et al. Accordingly, whether the autologous and allogeneic use of cardiac c-kit+ CSCs in clinical protocols for cardiac repair is or it is not appropriate cannot be determined from the data presented by van Berlo et al. What is needed to make this determination are additional experimental data, using genetically labelled eCSCs in clinically relevant animal models, which allow determining the fate of the transplanted eCSCs, their mode of action (direct participation or paracrine action) and quantification of their participation in the putative regenerative process. Most of these data have already been obtained. Therefore, the proposal for a moratorium on the on-going phase I/II clinical trials with c-kit+ eCSCs is premature. a.-To determine whether the expression of the test gene which has been modified to express Cre by a knock-in strategy maintains a temporal and spatial pattern of expression identical to the WT gene and the unmodified allele; NO b.-To determine whether the introduction of Cre into the locus of interest turns off or reduces its expression generating an hypomorph or even a complete hemyzyguous animal which might have an abnormal phenotype;
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